Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.50 |
| ▸ | MMP2 | P08253 | 8/20 | 0.50 |
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | MMP9 | P14780 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077382 | 0.84 | NPC1 (0.52) | MMP13MMP1ALDH1A1LMNAMAPT | |
| SCHEMBL1807247 | 0.79 | MMP13 (0.60) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL3544712 | 0.78 | RAB9A (0.35) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29677688 | 0.77 | MMP13 (0.59) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL3551333 | 0.77 | ALDH1A1 (0.41) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL3545624 | 0.77 | MMP1 (0.44) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2077470 | 0.76 | ALDH1A1 (0.40) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL1421532 | 0.76 | MMP2 (0.49) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL1431231 | 0.71 | MMP13 (0.59) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL16057689 | 0.71 | MMP13 (0.49) | MMP13MMP2MMP1MMP9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MMP13 4297/4885MMP2 4446/4885MMP1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.